In anticancer therapy, the HDAC inhibitors were tested as therapeutic agents for different types of tumours including but not limited to glioblastoma [49], multiple myeloma [50,51,52], T-cell lymphoma [53], breast cancers [54], and lymphoproliferative disorders [55,56,57]. Here, HDAC9 is linked to plasma cell myeloma.